Loading...
Market
How will Ozempic's market share in diabetes medications change by end of 2025 due to Alzheimer's findings?
2
Resolution / Starting Odds
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
No significant change • 25%
Market analysis reports from reputable financial analysts
Story
Novo Nordisk's Ozempic Linked to Significantly Reduced Alzheimer's Risk in Type 2 Diabetes Patients
Oct 24, 2024, 11:08 AM
Novo Nordisk's diabetes medication, Ozempic, has been linked to a significantly reduced risk of Alzheimer's disease, according to a new observational study. The research highlights the drug's potential effects beyond its primary uses for type 2 diabetes and obesity. This finding adds to the growing body of evidence surrounding Ozempic, which is already popular for its benefits in managing diabetes and assisting with weight loss. The study's results are particularly relevant for patients with type 2 diabetes, who may face an increased risk of developing Alzheimer's disease.
View original story
Similar markets
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
No significant change • 25%
Yes • 50%
No • 50%
Increase by over 10% • 25%
Increase by 5-10% • 25%
No significant change • 25%
Decrease • 25%
Adopted in US and EU • 25%
Adopted in US only • 25%
Adopted in EU only • 25%
Not adopted • 25%
Increased Sales • 25%
Decreased Sales • 25%
No Significant Change • 25%
Product Recall • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Below 40% • 25%
40% - 50% • 25%
50% - 60% • 25%
Above 60% • 25%
Above 50% • 25%
30%-50% • 25%
10%-30% • 25%
Below 10% • 25%
Mostly positive • 25%
Mixed • 25%
Mostly negative • 25%
No significant change • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%